We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

24 Jul 2026 - 26 Jul 2026

Handheld Optical Device Screens for Early Necrotizing Enterocolitis in Preterm Infants

By HospiMedica International staff writers
Posted on 18 Jun 2026

Necrotizing enterocolitis (NEC) is a sudden, rapidly progressive intestinal disease of premature infants that can lead to sepsis, surgery, and death. More...

Clinicians struggle to recognize NEC at its earliest stages before damage becomes visible on imaging. Early identification could enable timely medical therapy and reduce operative risk. To help address this challenge, investigators have developed a noninvasive optical device to screen preterm infants for early signs of NEC.

Broadband optical spectroscopy (BOS) was developed at Ann & Robert H. Lurie Children’s Hospital of Chicago in collaboration with a biomedical engineering laboratory at Northwestern University. The handheld device is designed for bedside use in the neonatal intensive care unit. The first-in-human study reporting its clinical use has been published in the Journal of Pediatric Surgery. The technology aims to detect NEC earlier than radiography can.

The BOS probe is placed gently on the infant’s abdomen. It measures infrared light reflected from the intestines and analyzes spectral signatures for changes in color that surgeons recognize as indicative of threatened intestinal tissue in NEC. The assessment is completed within about two minutes and does not expose infants to pain or radiation.

In the initial clinical evaluation, investigators tested BOS in 96 premature infants who were younger than 36 weeks’ gestation. Infants with congenital cardiac conditions or abdominal wall defects were excluded. The study found that BOS was safe and feasible in this population and produced detectable signal changes in infants with NEC. The findings support further validation of BOS as a screening modality to identify earlier stages of disease, when antibiotic therapy may still be effective.

“Our results show that BOS is a safe and feasible technology that produced detectable signal changes in premature infants with NEC. These findings suggest that BOS is a promising and potentially groundbreaking modality for screening and early detection of NEC,” said Seth Goldstein, MD, MPhil, pediatric general and thoracic surgeon at Lurie Children’s and Associate Professor of Surgery at Northwestern University Feinberg School of Medicine.

Related Links
Ann & Robert H. Lurie Children’s Hospital of Chicago
Northwestern University Feinberg School of Medicine


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Blood Pressure Monitor
Cuff Blood Pressure Monitor
New
Radiology Monitor
Barco MDNC-12130 Nio Fusion 12MP Radiology Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.